Eli Lilly and Company
CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma

Abstract:

The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine.a- bout.2.about.carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.